Emerging treatments
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Rosenthal A et al. Br J Haematol. 2015 Sep 25. doi: 10.1111/bjh.13765. [Epub ahead of print]. Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma. Shah JJ et al. Blood. 2015 Sep 17. pii: blood-2015-05-643320. [Epub ahead of print].…
Details